Francesco Angotzi (Federica Frezzato, Livio Trentin)

ORCID

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 18

Top Venues

Hematological oncology

Current oncology (Toronto, Ont.)

British journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Andrea Serafin, Alessandro Cellini, Chiara Adele Cavarretta, Valeria Ruocco, Francesco Angotzi, Ivan Zatta, Federica Frezzato, Laura Bonaldi, Annalisa Martines, Stefano Pravato, Francesco Piazza, Livio Trentin, Andrea Visentin
Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax-based regimens. British journal of haematology 205 (1) (2024)
Enrica Antonia Martino, Francesca Romana Mauro, Gianluigi Reda, Luca Laurenti, Andrea Visentin, Anna Maria Frustaci, Ernesto Vigna, Sara Pepe, Gioacchino Catania, Giacomo Loseto, Roberta Murru, Annalisa Chiarenza, Paolo Sportoletti, Maria Ilaria Del Principe, Roberta Laureana, Marta Coscia, Sara Galimberti, Eleonora Ferretti, Antonella Zucchetto, Riccardo Bomben, Jerry Polesel, Alessandra Tedeschi, Davide Rossi, Francesco Angotzi, Antonino Neri, Fortunato Morabito, Valter Gattei, Massimo Gentile
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort. Hematological oncology 42 (1) (2024)
Andrea Serafin, Alessandro Cellini, Chiara Adele Cavarretta, Valeria Ruocco, Francesco Angotzi, Ivan Zatta, Federica Frezzato, Laura Bonaldi, Annalisa Martines, Stefano Pravato, Francesco Piazza, Livio Trentin, Andrea Visentin
Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax-based regimens. British journal of haematology (2024)
Nayla Mouawad, Edoardo Ruggeri, Guido Capasso, Leonardo Martinello, Andrea Visentin, Francesco Angotzi, Federica Frezzato
How receptor tyrosine kinase-like orphan receptor 1 meets its partners in chronic lymphocytic leukemia. Hematological oncology 42 (2) (2024)
Enrica Antonia Martino, Francesca Romana Mauro, Gianluigi Reda, Luca Laurenti, Andrea Visentin, Anna Maria Frustaci, Ernesto Vigna, Sara Pepe, Gioacchino Catania, Giacomo Loseto, Roberta Murru, Annalisa Chiarenza, Paolo Sportoletti, Maria Ilaria Del Principe, Roberta Laureana, Marta Coscia, Sara Galimberti, Eleonora Ferretti, Antonella Zucchetto, Riccardo Bomben, Jerry Polesel, Alessandra Tedeschi, Davide Rossi, Francesco Angotzi, Antonino Neri, Fortunato Morabito, Valter Gattei, Massimo Gentile
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort. Hematological oncology 42 (1) (2024)
Nayla Mouawad, Edoardo Ruggeri, Guido Capasso, Leonardo Martinello, Andrea Visentin, Francesco Angotzi, Federica Frezzato
How receptor tyrosine kinase-like orphan receptor 1 meets its partners in chronic lymphocytic leukemia. Hematological oncology 42 (2) (2024)
Paolo Sportoletti, Luca Laurenti, Annalisa Chiarenza, Gianluca Gaidano, Elisa Albi, Francesca Romana Mauro, Francesco Angotzi, Daniele Vallisa, Fabrizio Pane, Antonio Cuneo, Francesco Albano, Giulia Zamprogna, Marta Coscia, Alessandro Gozzetti, Gianluigi Reda, Morena Caira, Paola Finsinger, Giuliana Gualberti, Emilia Iannella, Simona Malgieri, Stefano Molica
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study. Hematological oncology (2023)
Annalisa Martines, Angela Grassi, Andrea Visentin, Monica Facco, Silvia Nalio, Valeria Sacchetto, Elisa Pagnin, Alessandro Cellini, Roberta Bertorelle, Francesco Angotzi, Laura Bonaldi
The added value of karyotype in predicting the need for therapy in chronic lymphocytic leukemia with 13q deletion. Hematological oncology (2023)
Francesco Autore, Idanna Innocenti, Gianluigi Reda, Andrea Visentin, Candida Vitale, Alfonso Piciocchi, Alberto Fresa, Monica M A Leone, Lucia Farina, Giulia Quaresmini, Claudia Baratè, Annamaria Giordano, Angela Ferrari, Ilaria Angeletti, Maria Rosaria De Paolis, Lara Malerba, Federico Chiurazzi, Giacomo Loseto, Gioacchino Catania, Paolo Sportoletti, Ilaria Scortechini, Riccardo Moia, Massimo Gentile, Gian Matteo Rigolin, Veronica Mattiello, Valter Gattei, Marta Coscia, Francesco Angotzi, Robin Foà, Antonio Cuneo, Luca Laurenti
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study. Hematological oncology (2023)
Andrea Visentin, Maria Chiara Molinari, Stefano Pravato, Alessandro Cellini, Francesco Angotzi, Chiara Adele Cavaretta, Valeria Ruocco, Silvia Imbergamo, Francesco A Piazza, Giulia Proietti, Francesca Romana Mauro, Livio Trentin
A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency. Current oncology (Toronto, Ont.) 30 (1) (2022)
Alberto Biggi, Stephane Chauvie, Federico Fallanca, Luca Guerra, Fabrizio Bergesio, Massimo Menga, Andrea Bianchi, Michele Gregianin, Agostino Chiaravalloti, Orazio Schillaci, Chiara Pavoni, Caterina Patti, Marco Picardi, Alessandra Romano, Corrado Schiavotto, Roberto Sorasio, Simonetta Viviani, Giorgio La Nasa, Francesco Angotzi, Alessandro Rambaldi, Andrea Gallamini
Predictive value on advance Hodgkin Lymphoma treatment outcome of end-of treatment FDG PET/CT in the HD0607 clinical trial. Hematological oncology (2022)
Alberto Biggi, Stephane Chauvie, Federico Fallanca, Luca Guerra, Fabrizio Bergesio, Massimo Menga, Andrea Bianchi, Michele Gregianin, Agostino Chiaravalloti, Orazio Schillaci, Chiara Pavoni, Caterina Patti, Marco Picardi, Alessandra Romano, Corrado Schiavotto, Roberto Sorasio, Simonetta Viviani, Giorgio La Nasa, Francesco Angotzi, Alessandro Rambaldi, Andrea Gallamini
Predictive value on advance hodgkin lymphoma treatment outcome of end-of treatment FDG PET/CT in the HD0607 clinical trial. Hematological oncology (2022)
Michele Merli, Isacco Ferrarini, Francesco Merli, Alessandro Busca, Roberto Mina, Brunangelo Falini, Riccardo Bruna, Roberto Cairoli, Monia Marchetti, Alessandra Romano, Michele Cavo, Luca Arcaini, Francesco Angotzi, Chiara Cattaneo, Enrico Derenzini, Nicola Stefano Fracchiolla, Francesco Marchesi, Annamaria Scattolin, Atto Billio, Monica Bocchia, Massimo Massaia, Carlo Gambacorti-Passerini, Francesca Romana Mauro, Massimo Gentile, Sara Mohamed, Matteo Giovanni Della Porta, Elisa Coviello, Daniela Cilloni, Giuseppe Visani, Augusto Bramante Federici, Maria Chiara Tisi, Laura Cudillo, Sara Galimberti, Filippo Gherlinzoni, Livio Pagano, Anna Guidetti, Lorenza Bertù, Paolo Corradini, Francesco Passamonti, Carlo Visco
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort. Hematological oncology (2022)
Andrea Visentin, Maria Chiara Molinari, Stefano Pravato, Alessandro Cellini, Francesco Angotzi, Chiara Adele Cavaretta, Valeria Ruocco, Silvia Imbergamo, Francesco A Piazza, Giulia Proietti, Francesca Romana Mauro, Livio Trentin
A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency. Current oncology (Toronto, Ont.) 30 (1) (2022)
Andrea Visentin, Maria Chiara Molinari, Stefano Pravato, Alessandro Cellini, Francesco Angotzi, Chiara Adele Cavaretta, Valeria Ruocco, Silvia Imbergamo, Francesco A Piazza, Giulia Proietti, Francesca Romana Mauro, Livio Trentin
A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency. Current oncology (Toronto, Ont.) 30 (1) (2022)
Andrea Visentin, Maria Chiara Molinari, Stefano Pravato, Alessandro Cellini, Francesco Angotzi, Chiara Adele Cavaretta, Valeria Ruocco, Silvia Imbergamo, Francesco A Piazza, Giulia Proietti, Francesca Romana Mauro, Livio Trentin
A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency. Current oncology (Toronto, Ont.) 30 (1) (2022)
Andrea Visentin, Maria Chiara Molinari, Stefano Pravato, Alessandro Cellini, Francesco Angotzi, Chiara Adele Cavaretta, Valeria Ruocco, Silvia Imbergamo, Francesco A Piazza, Giulia Proietti, Francesca Romana Mauro, Livio Trentin
A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency. Current oncology (Toronto, Ont.) 30 (1) (2022)
Andrea Visentin, Maria Chiara Molinari, Stefano Pravato, Alessandro Cellini, Francesco Angotzi, Chiara Adele Cavaretta, Valeria Ruocco, Silvia Imbergamo, Francesco A Piazza, Giulia Proietti, Francesca Romana Mauro, Livio Trentin
A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency. Current oncology (Toronto, Ont.) 30 (1) (2022)

Francesco Angotzi.css-eqlu8i{font-size:small;padding-left:4px;} (Federica Frezzato, Livio Trentin)

Publication Activity (10 Years)

Top Topics

Top Venues

Francesco Angotzi (Federica Frezzato, Livio Trentin)